BBUSvsIBB
JPMorgan BetaBuilders U.S. Equity ETF against iShares Biotechnology ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BBUS | IBB | |
|---|---|---|
| Expense ratio | 0.020% | 0.45% |
| Assets | $9.3B | $10.7B |
| Net flow, 1 month | +$173M | +$656M |
| Net flow, 1 year | +$2.6B | +$2.2B |
| Return, YTD | +11.8% | +22.0% |
| Return, 1 year | +13.8% | +38.7% |
| Avg daily volume | 250K | 1.5M |
| Holdings | 575 | 221 |
| Listed | Mar 11, 2019 | Feb 5, 2001 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS